On August 30, 2016, our very own
Jeffrey Whitman, President and Chief Surgeon at Key-Whitman Eye Center, will join Dr.
Stephen Slade at Dr. Slade’s Houston-based eye surgery center to
perform the first Raindrop® Near Vision Inlay commercial procedures
in the nation.
On June 29, 2016, after a thorough clinical trial period, the Food and
Drug Administration (FDA) approved these small, clear implantable medical
devices to improve vision in eligible patients with presbyopia.
Dr. Whitman, who performed more Raindrop® procedures than any other
eye surgeon in the nation during clinical trials, states, “The best
candidates for the Raindrop inlay are people who are not dependent on
glasses or contact lenses for distance vision but need vision correction
to read close up. For example, if you’re in your 40s or 50s, and
have become increasingly dependent on readers, Raindrop may be a good
option for you.”
Both Dr. Whitman and investigators were pleased with the improvements patients
experienced to both intermediary and near vision after the Raindrop®
procedure. In fact, patients witnessed five lines of improved near vision
and two to three lines of improvement to intermediary vision following
the procedure. Additionally, patients lost negligible distance vision.
Because Dr. Whitman performed the most procedures during the clinical trials
and Dr. Slade was amongst the first investigators in the Raindrop®
study, the developing and manufacturing company of the Raindrop® Near
Vision Inlay asked them to perform the first commercial post-FDA approval
surgeries in the nation.
Dr. Whitman and Dr. Slade will each perform the Raindrop® surgery on
two to three patients on August 30. The procedure and Q&A will broadcast
that day at 10:00 AM Central Time on EyeTube.net.